Cover Image

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019-2022

BackgroundThe DTaP-Hib and DTaP-IPV/Hib combination vaccine can be used as a substitute for the diphtheria, tetanus, and acellular pertussis combined vaccine (DTaP). We aimed to evaluate the safety of multi-component vaccines containing DTaP by analyzing the reporting rates and characteristics of ad...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qinghua Chen (Author), Chuandi Zhang (Author), Chunmei Ye (Author), Junwei Zhu (Author), Jie Shen (Author), Chang Zhu (Author), Pai Yang (Author), Tiane Liu (Author), Yuyang Xu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study
by: Yiqing Zhu, et al.
Published: (2024)

Proactive surveillance on DTaP vaccination-induced adverse local reac-tions among infants in a county of Jiangsu province
by: Peng ZHANG, et al.
Published: (2024)

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)
by: Andrea Guerra, et al.
Published: (2024)

Improving childhood vaccination coverage rates: the case of fourth dose of DTaP
by: Sarah J. Clark, et al.
Published: (2020)

The Implementation of Pentavalent Vaccine DTaP/IPV/Hib within National Immunization Schedule
by: Irina V. Mikheeva, et al.
Published: (2019)

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients
by: Andrew Dakin, et al.
Published: (2023)

Immunogenicity and safety of DTaP/Hib combined vaccination at different inoculation sites among infants
by: Zhen-jiang LIU, et al.
Published: (2022)

DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers
by: Andrew W. Lee, et al.
Published: (2017)

DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure
by: Florence Boisnard, et al.
Published: (2023)

Innovation of Shallot (Allium Ascalonicum L) Essential Oil for Fever Reduction in Infants Post DTaP Immunization
by: Setiawandari Setiawandari, et al.
Published: (2021)

Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children
by: Soon Min Lee, et al.
Published: (2019)

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants
by: Marissa B. Wilck, et al.
Published: (2021)

Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: A rare pediatric case report and review of literature
by: Meichen Pan, et al.
Published: (2023)

Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China
by: Aodi Huang, et al.
Published: (2024)

Immunogenicity and safety of a DTaP-IPV//PRP~T combination vaccine given with hepatitis B vaccine: a randomized open-label trial
by: Maria Rosario Capeding, et al.
Published: (2008)

Rejoinder to comments on ''Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China''
by: Floriano Amimo
Published: (2024)

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants
by: Yoshiyuki Tanaka, et al.
Published: (2017)

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously
by: Anitta Ahonen, et al.
Published: (2022)

A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants
by: Diego Mpia Elenge, et al.
Published: (2024)

Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months
by: Pope Kosalaraksa, et al.
Published: (2018)

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
by: Xuejiao Pan, et al.
Published: (2022)

Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021
by: Dongmei Gao, et al.
Published: (2023)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
by: Colleen M. Kingsbury, et al.
Published: (2024)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

Use of electronic immunization registry in the surveillance of adverse events following immunization
by: Ana Paula Sayuri Sato, et al.
Published: (2018)

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
by: The MMR-158 Study Group
Published: (2019)

Active surveillance study of adverse events following immunisation of children in the Czech Republic
by: Jana Danova, et al.
Published: (2017)

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020
by: Li Sun, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

A DTAP-IPV//PRP~T VACCINE: A REVIEW OF 16 YEARS' CLINICAL EXPERIENCE
by: Stanley A. Plotkin, et al.
Published: (2012)

Application of TGA/c-DTA for Distinguishing between Two Forms of Naproxen in Pharmaceutical Preparations
by: Paweł Ramos, et al.
Published: (2023)

Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system
by: Yifeng Bai, et al.
Published: (2024)

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
by: Marwan A. Alrasheed, et al.
Published: (2024)

Smallpox Vaccination Outcomes and Adverse Event Surveillance of 18 Counties in North Central Florida
by: Jerne Shapiro, et al.
Published: (2006)

Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022
by: Jinghui WANG, et al.
Published: (2024)

REACTOGENITY AND SAFETY OF ADSORBED VACCINES AGAINST DIPHTERIA, TETANUS AND PERTUSSIS (DTAP): OBSERVATIONAL MULTICENTRAL TRIAL
by: V.K. Tatochenko, et al.
Published: (2006)

REACTOGENITY AND SAFETY OF ADSORBED VACCINES AGAINST DIPHTERIA, TETANUS AND PERTUSSIS (DTAP): OBSERVATIONAL MULTICENTRAL TRIAL
by: V.K. Tatochenko, et al.
Published: (2006)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital
by: Naveena Mary Cherian, et al.
Published: (2023)